Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Urotronic Offers New Hope for Men Suffering from Urethral Strictures

PRWeb Tuesday, 7 November 2017 ()
U.S. Food and Drug Administration (FDA) Approves Clinical Trial of drug-coated balloon catheter

Plymouth, MN (PRWEB) November 07, 2017

Doctors are beginning a clinical study of a new a new medical solution that could dramatically change the way urethral strictures are treated today for millions of men around the world.

The Optilume™ drug-coated balloon (DCB), developed by Urotronic, based in Plymouth, MN, represents the first substantial investment in urology in a medtech field often dominated by advancements in cardiology and oncology.

“It’s exciting to see investment to treat this disease and to see a new product being offered for really the first time in history,” says Dr. Sean Elliott, who directs the program in reconstructive urological surgery at the University of Minnesota.

Dr. Elliott is the principal investigator of the FDA-approved clinical trial of Optilume. The U.S. based trial, known as ROBUST II, recently received FDA approval for an Investigational Device Exemption (IDE). The early feasibility study will be conducted at 5 medical centers around the country including the University of Iowa, University of Utah, Eastern Virginia Medical Center and the University of Minnesota and Metro Urology in Minneapolis.

There are roughly 1.5 million doctors’ office visits in the U.S. to treat urethral strictures, which block the pathway for urine to exit the body from the bladder and can result in a painful, frustrating slowing of the urinary system. Urethral strictures are often caused by infections, trauma and other medical procedures that injure the lining of the urethra. The number of urological procedures is expected to grow rapidly as Baby Boomers age and are more susceptible to urinary tract problems, according to doctors involved in the clinical trial.

The most common treatments, balloon dilation and another endoscopic intervention known as an urethrotomy, both have high rates of recurrence. An open surgical procedure called urethroplasty, another treatment option for urethral stricture, has a much better success rate however, it may require a longer recovery and includes painful side effects.

“Men, in general cringe at the idea of an open urethroplasty and much prefer something that can be done without cutting open the genital area,” says Elliott. “The numbers speak for themselves. Close to 95-98% of urethral strictures in the United States are treated with endoscopic means, meaning with a dilation or urethrotomy.”

That’s why Dr. Elliott and his colleagues around the world are so interested in the ROBUST II clinical trial. For them, and millions of men around the world, the drug-coated balloon solution represents a potential treatment option that could be more effective in treating urethral strictures without painful, surgical side effects.

“We're optimistic that the drug coated balloon catheter will dramatically improve the quality of life of men suffering daily from the symptoms of urethral strictures,” says Dr. Jessica DeLong, with Eastern Virginia Medical Center. “There’s added benefit that this procedure would have a much shorter recovery and lower risks than an open surgical urethroplasty.

As with other medtech advancements it is the drug-coated balloon that could be a difference maker. Scar tissue quickly develops after any medical intervention. The Optilume DCB combines balloon dilation, to expand or widen the strictured area, and the delivery of an anti-proliferative drug which has already been proven effective at limiting scar tissue generation in cardiovascular applications.

“The fact that they thought about adding the drug, I think that’s the ingenious part,” says Dr. Ramon Virasoro, who practices with Dr. DeLong at Urology of Virginia. “This is a problem that makes people very unhappy and a lack of an effective minimally invasive treatment option can lead men to delay care to the point where it really affects their quality of life.”

Urotronic’s solution may also be a response to changes underway in healthcare delivery where the emphasis is shifting to outcomes as opposed to fee-for-service models.

The American Urological Association recently updated its treatment guidelines to include a discussion of the most effective treatments for men with recurrent urethral strictures. Dr. Elliott says treatments have actually undergone very few changes in centuries.

“If the drug-coated balloon proves to be effective, that would really change the game in how I am counseling patients,” he said.

Dr. Elliott and other investigators will monitor the progress of the ROBOUST II clinical trial, which get underway shortly and will follow the patients for a period of five years. The FDA will monitor the progress as well.

The Optilume DCB is an investigational device, not available for sale. CAUTION- Investigational Device. Limited by Federal (or United States) law to investigational use.

About Urotronic, Inc.
Urotronic, Inc., headquartered in Plymouth, Minnesota, is an early stage medical device company currently conducting clinical trials to support global commercialization of their products. The Optilume™ drug-coated balloon technology provides a low cost, minimally-invasive treatment option for men suffering from urinary track conditions like benign prostatic hyperplasia (BPH), urethral and ureteral strictures, and bladder neck contractures (BNC). The prevalence of BPH and lower urinary tract issues rises markedly with increased age. BPH affects 70% of men 60-69 years of age and 80% of those 70 years of age or older. The drug-coated balloon technology under development creates a paradigm change from the methods currently used by urologists to treat these conditions. For more information on Urotronic and our products, please visit us at urotronic.com
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

You Might Like


Other recent news in Press Releases

Top Nintendo Switch, Xbox One & PS4 BLACK FRIDAY & Cyber Monday Deals for 2017: Topic Reviews Compare The Best Gaming DealsScore Killer Security Camera Deals on Reolink for Black Friday CYBER MONDAY 2017
Blockbuster Special Effects, Title Templates and More – Filmora Effects Store’s BLACK FRIDAY DEALS for All Video CreatorsKorean chickens will be served at dining tables in Vietnam and HONG KONG
Adoption of Telematics to Boost the Car Rental Market in EUROPE | TechnavioNintendo Download: HAPPY THANKSGIVING!
vhf camfacture AG – Milling and Grinding Machine for Same-day Dentistry: NORTH AMERICAN Launch of the Z4Glancy Prongay & MURRAY LLP Commences Investigation on Behalf of Alkermes plc Investors (ALKS)
GLORY’s Dynamix Software Certified under LATEST PCI-DSS StandardStabilize a CHRISTMAS Tree with TREE STRAIGHT, Developed by Two InventHelp Inventors

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+